Summary of: Bartlett CH, Mardekian J, Yu-Kite M, Cotter MJ, Kim S, Decembrino J, Snow T, Carson KR, Rockland JM, Kraus AL, Wilner KD, Oharu N, Schnell P, Lu D, Tursi J. Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET). Poster presented at: 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO); June, 2019; Chicago, IL.
Real-world evidence helped provide data of the use of palbociclib in males with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Analysis of de-identified claims data and de-identified EHR-derived Flatiron data on men with HR+, HER2- metastatic breast cancer treated in combination with palbociclib in the real world supported the FDA’s expansion of the palbociclib approval, previously only approved in women, to include men with HR+, HER2- metastatic breast cancer.